Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from 4SC AG ( (DE:VSC) ).
4SC AG announced that the European Medicines Agency (EMA) has provided feedback on its marketing authorisation application for resminostat, an orphan medicinal product for treating cutaneous T-cell lymphoma (CTCL). The EMA’s assessment report indicated that the application is currently not approvable due to major objections. 4SC AG plans to evaluate the feedback and determine the best course of action to address the EMA’s concerns within the given one-month response deadline.
More about 4SC AG
4SC AG is a biotechnology company based in Planegg-Martinsried, Germany, and is listed on the Frankfurt Stock Exchange. The company focuses on developing small molecule drugs for cancer and autoimmune diseases, with a particular emphasis on epigenetic and cancer immunotherapy treatments.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €56.71M
Learn more about VSC stock on TipRanks’ Stock Analysis page.